Keywords: Biogen Ided, Forest, Gilead, Third Second quarter 2009, Financial results
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
Article | 21 October 2009
With the US third-quarter financial results reporting season building up steam, there were some positive figures coming out from mid-cap ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
